SCNI
Scinai Immunotherapeutics Ltd. (SCNI) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative cash conversion cycle of -40.4 days indicates working-capital efficiency versus peers, supporting liquidity despite weak profitability.
Debt-to-equity of 0.31 suggests moderate leverage, leaving balance-sheet flexibility relative to more indebted small-cap peers.
Current and quick ratios of 1.56 imply near-term coverage above 1.0, reducing refinancing pressure versus weaker-liquidity competitors.
ROIC of -55.0% is structurally poor, but the metric still highlights capital deployment discipline as the key peer benchmark for turnaround potential.
Weaknesses
ROIC of -55.0% signals severe value destruction versus peers, indicating the business is not yet converting invested capital into returns.
Absence of reported operating and gross margins limits transparency, but the available profitability profile remains materially weaker than profitable peers.
Debt-to-equity of 0.31 is manageable, yet leverage still constrains flexibility more than cash-rich peers with stronger earnings coverage.
Liquidity ratios near 1.56 are adequate, but they remain only moderate versus stronger peers that typically sustain larger buffers through cycles.
Opportunities
If working-capital efficiency persists, the negative cash conversion cycle can continue supporting self-funding versus peers that absorb cash to grow.
Improving ROIC from deeply negative levels would create the largest relative re-rating opportunity, because peers with positive returns already compound capital.
Moderate leverage leaves room for operational improvement to translate into equity value faster than for more levered competitors.
Stronger disclosure of margins and segment economics could narrow the information gap versus peers and improve investor comparability.
Threats
Persistently negative ROIC threatens long-term competitiveness versus peers, because capital intensity without returns erodes strategic flexibility and valuation.
If working-capital benefits reverse, the current cash advantage could disappear quickly, exposing the company to tighter liquidity than peers.
Limited margin disclosure increases uncertainty relative to better-reported competitors, making it harder to evidence durable operating improvement.
Small-cap peers with positive profitability and stronger balance sheets can outcompete SCNI for capital, customers, and strategic optionality.
Overall Score
SCNI’s structural positioning is weak versus peers because severe negative ROIC outweighs acceptable liquidity and moderate leverage, leaving only limited near-term resilience.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Scinai Immunotherapeutics Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
